Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Reni M, Pasetto LM, Passardi A, Milella M, Mambrini A, Cereda S, Aprile G, Tronconi MC, Berardi R, Cordio S, Sartori N, Rognone A, Pederzoli P, Falconi M. Reni M, et al. Among authors: tronconi mc. Dig Liver Dis. 2011 Mar;43(3):225-30. doi: 10.1016/j.dld.2010.09.010. Epub 2010 Nov 2. Dig Liver Dis. 2011. PMID: 21044873
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pederzoli P, Falconi M. Reni M, et al. Among authors: tronconi mc. Anticancer Drugs. 2010 Apr;21(4):459-64. doi: 10.1097/CAD.0b013e328336f50e. Anticancer Drugs. 2010. PMID: 20110805
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Aschele C, et al. Among authors: tronconi mc. J Clin Oncol. 2011 Jul 10;29(20):2773-80. doi: 10.1200/JCO.2010.34.4911. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606427 Clinical Trial.
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E. Reni M, et al. Among authors: tronconi mc. Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12. Ann Surg Oncol. 2012. PMID: 22237835 Clinical Trial.
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Santoro A, Gebbia V, Pressiani T, Testa A, Personeni N, Arrivas Bajardi E, Foa P, Buonadonna A, Bencardino K, Barone C, Ferrari D, Zaniboni A, Tronconi MC, Cartenì G, Milella M, Comandone A, Ferrari S, Rimassa L. Santoro A, et al. Among authors: tronconi mc. Ann Oncol. 2015 Mar;26(3):542-7. doi: 10.1093/annonc/mdu576. Epub 2014 Dec 23. Ann Oncol. 2015. PMID: 25538178 Free article. Clinical Trial.
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L, Bozzarelli S, Pietrantonio F, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A. Rimassa L, et al. Among authors: tronconi mc. Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14. Clin Colorectal Cancer. 2019. PMID: 30846365 Clinical Trial.
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: tronconi mc. Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12. Eur J Cancer. 2010. PMID: 20708923 Clinical Trial.
35 results